Year None20242023202220212020201920182017201620152014201320122011201020092008 Jan 08, 2024 Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio Read More PDF Version Jan 03, 2024 Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia Read More PDF Version Jan 02, 2024 Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 Read More PDF Version Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 13 of 13
Jan 08, 2024 Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio Read More PDF Version
Jan 03, 2024 Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia Read More PDF Version
Jan 02, 2024 Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 Read More PDF Version